Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, et al. Grand challenges in global mental health. Nature. 2011;475:27.
Subbaraman MS, Lendle S, van der Laan M, Kaskutas LA, Ahern J. Cravings as a mediator and moderator of drinking outcomes in the COMBINE study. Addiction. 2013;108:1737–44.
Cavicchioli M, Vassena G, Movalli M, Maffei C. Is craving a risk factor for substance use among treatment-seeking individuals with alcohol and other drugs use disorders? A meta-analytic review. Drug Alcohol Depend. 2020;212:108002.
Stohs ME, Schneekloth TD, Geske JR, Biernacka JM, Karpyak VM. Alcohol Craving Predicts Relapse After Residential Addiction Treatment. Alcohol Alcohol. 2019;54:167–72.
Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol: Clin Exp Res. 1999;23:1289–95.
Kranzler HR, Mulgrew CL, Modesto-Lowe V, Burleson JA. Validity of the Obsessive Compulsive Drinking Scale (OCDS): does craving predict drinking behavior? Alcohol Clin Exp Res. 1999;23:108–14.
Kalra G, Sousa AD, Shrivastava A. Disulfiram in the management of alcohol dependence: A comprehensive clinical review. Open J Psychiatry. 2014;01:10.
Skinner MD, Lahmek P, Pham H, Aubin H-J. Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis. PLOS ONE. 2014;9:e87366.
Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. Addict Biol. 2017;22:1515–27.
McHugh RK, Fitzmaurice GM, Griffin ML, Anton RF, Weiss RD. Association between a brief alcohol craving measure and drinking in the following week. Addiction (Abingdon, Engl). 2016;111:1004–10.
Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-Assisted Treatment for Opioid-Use Disorder. Mayo Clin Proc. 2019;94:2072–86.
Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010;9:13–22.
Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H. Opioid modulators for alcohol dependence. Expert Opin Investig Drugs. 2011;20:1073–86.
Mason BJ, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets. 2010;9:23–32.
Shen WW. Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacol Rep. 2018;38:105–16.
Más-Serrano P, Granero L, Martín-Algarra RV, Guerri C, Polache A. Kinetic study of acamprosate absorption in rat small intestine. Alcohol Alcohol. 2000;35:324–30.
Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77:315–23.
Witkiewitz K, Saville K, Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Therap Clin risk Manag. 2012;8:45–53.
Karpyak VM, Biernacka JM, Geske JR, Jenkins GD, Cunningham JM, Rüegg J, et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry. 2014;4:e453.
Karpyak VM, Geske JR, Hall-Flavin DK, Loukianova LL, Schneekloth TD, Skime MK, et al. Sex-specific association of depressive disorder and transient emotional states with alcohol consumption in male and female alcoholics. Drug Alcohol Depend. 2019;196:31–9.
Biernacka JM, Coombes BJ, Batzler A, Ho AM-C, Geske JR, Frank J, et al. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021;46:2132–9.
Ho M-F, Zhang C, Moon I, Coombes BJ, Biernacka J, Skime M, et al. Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder. Front Pharmacol. 2022;13:986238.
Ho M-F, Zhang C, Wei L, Zhang L, Moon I, Geske JR, et al. Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. Br J Pharmacol. 2022;173:16.
Ho MF, Zhang C, Moon I, Wei L, Coombes B, Biernacka J, et al. Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: molecular links between the SNHG16 locus and catecholamine metabolism. Mol Metab. 2022;63:101534.
Hinton DJ, Vázquez MS, Geske JR, Hitschfeld MJ, Ho AMC, Karpyak VM, et al. Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. Sci Rep. 2017;7:2496.
Brenner E, Tiwari GR, Kapoor M, Liu Y, Brock A, Mayfield RD. Single cell transcriptome profiling of the human alcohol-dependent brain. Hum Mol Genet. 2020;29:1144–53.
Spanagel R. Animal models of addiction. Dialogues Clin Neurosci. 2017;19:247–58.
Ho M-F, Zhang C, Zhang L, Wei L, Zhou Y, Moon I, et al. TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. Mol Psychiatry. 2020;26:3122–33.
Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515:414–8.
Qian X, Jacob F, Song MM, Nguyen HN, Song H, Ming G-l. Generation of human brain region–specific organoids using a miniaturized spinning bioreactor. Nat Protoc. 2018;13:565.
Lira MC, Sarda V, Heeren TC, Miller M, Naimi TS. Alcohol Policies and Motor Vehicle Crash Deaths Involving Blood Alcohol Concentrations Below 0.08. Am J Preventive Med. 2020;58:622–9.
Mason BJ, Goodman AM, Dixon RM, Hameed MHA, Hulot T, Wesnes K, et al. A Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Acamprosate and Naltrexone. Neuropsychopharmacology. 2002;27:596.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma (Oxf, Engl). 2013;29:15–21.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545–50.
Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267.
Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
Ho MF, Low LM, Rose’Meyer RB. Pharmacology of the Adenosine A3 Receptor in the Vasculature and Essential Hypertension. PLoS One. 2016;11:e0150021.
Ray LA, Courtney KE, Bacio G, MacKillop J. The Assessment of Craving in Addiction Research. The Wiley-Blackwell Handbook of Addiction Psychopharmacology 2013, pp 345–80.
Coleman LG Jr, Crews FT. Innate Immune Signaling and Alcohol Use Disorders. Handb Exp Pharm. 2018;248:369–96.
Santos R, Vadodaria KC, Jaeger BN, Mei A, Lefcochilos-Fogelquist S, Mendes APD, et al. Differentiation of Inflammation-Responsive Astrocytes from Glial Progenitors Generated from Human Induced Pluripotent Stem Cells. Stem Cell Rep. 2017;8:1757–69.
Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57.
Petrasek J, Iracheta-Vellve A, Csak T, Satishchandran A, Kodys K, Kurt-Jones EA, et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc Natl Acad Sci. 2013;110:16544–9.
Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18:152.
Haass-Koffler CL, Leggio L, Kenna GA. Pharmacological approaches to reducing craving in patients with alcohol use disorders. CNS Drugs. 2014;28:343–60.
Leclercq S, De Saeger C, Delzenne N, de Timary P, Stärkel P. Role of Inflammatory Pathways, Blood Mononuclear Cells, and Gut-Derived Bacterial Products in Alcohol Dependence. Biol Psychiatry. 2014;76:725–33.
Leclercq S, de Timary P, Delzenne NM, Stärkel P. The link between inflammation, bugs, the intestine and the brain in alcohol dependence. Transl Psychiatry. 2017;7:e1048.
Erickson EK, Grantham EK, Warden AS, Harris RA. Neuroimmune signaling in alcohol use disorder. Pharmacol Biochem Behav. 2019;177:34–60.
Ray LA, Bujarski S, Shoptaw S, Roche DJ, Heinzerling K, Miotto K. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. Neuropsychopharmacology. 2017;42:1776–88.
Erickson EK, Blednov YA, Harris RA, Mayfield RD. Glial gene networks associated with alcohol dependence. Sci Rep. 2019;9:10949.
Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33:451–9.
Cant R, Dalgleish AG, Allen RL. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors. Front Immunol. 2017;8:809.
Liu YP, Zeng L, Tian A, Bomkamp A, Rivera D, Gutman D, et al. Endoplasmic reticulum stress regulates the innate immunity critical transcription factor IRF3. J Immunol (Baltim, Md: 1950). 2012;189:4630–9.
Smith JA. Regulation of Cytokine Production by the Unfolded Protein Response; Implications for Infection and Autoimmunity. Front Immunol. 2018;9:422.
Ji C. Mechanisms of Alcohol-Induced Endoplasmic Reticulum Stress and Organ Injuries. Biochem Res Int. 2012;2012:216450.
Pan J, Jin R, Shen M, Wu R, Xu S. Acamprosate Protects Against Adjuvant-Induced Arthritis in Rats via Blocking the ERK/MAPK and NF-κB Signaling Pathway. Inflammation. 2018;41:1194–9.
Sternberg Z, Cesario A, Rittenhouse-Olson K, Sobel RA, Leung YK, Pankewycz O, et al. Acamprosate modulates experimental autoimmune encephalomyelitis. Inflammopharmacology. 2012;20:39–48.
Moslehi A, Nabavizadeh F, Dehpour AR, Tavanga SM, Hassanzadeh G, Zekri A, et al. Naltrexone attenuates endoplasmic reticulum stress induced hepatic injury in mice. Acta Physiologica Hungarica. 2014;101:341–52.
Swift RM, Aston ER. Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry. 2015;23:122–33.
Bradshaw SD, Shumway ST, Dsauza CM, Morris N, Hayes ND. Hope, coping skills, and the prefrontal cortex in alcohol use disorder recovery. Am J Drug Alcohol Abus. 2017;43:591–601.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41398-024-02880-5